LUNAI BIOWORKS: CEO LETTER TO SHAREHOLDERS

Defense Contract Value

Not specified

The financial terms of the multi-year defense collaboration with BioSymetrics are not disclosed.

STTR Grant Amount

$1.85 million

Amount awarded to BioSymetrics for research on alcohol use disorder.

Share Trading Volume Peak

554 million shares

Peak trading volume on March 17, 2026, which was 15.3 times all outstanding shares.

§ 01 Executive Snapshot

What: Lunai Bioworks updates shareholders on strategic advancements in biotechnology and national security.
Who: Lunai Bioworks, U.S. government, BioSymetrics, Pathfinder Consortium, Harvard University, and other institutional partners.
Why it matters: The company's initiatives position it at the forefront of biodefense and precision neurology, areas of increasing national security relevance.

In April 2026, Lunai secured a revenue-generating, multi-year defense collaboration with BioSymetrics for AI-enabled chemical threat assessment.
Established the Pathfinder Consortium, partnering with leading institutions such as Harvard and the University of Utah to enhance biodefense capabilities.
Received a Phase I/II STTR grant of $1.85 million awarded to BioSymetrics for alcohol use disorder research, validating their biology-first discovery approach.

The convergence of AI and biotechnology is becoming critical in national security, particularly in addressing biological threats and pandemics.
The 2027 Defense Authorization Bill emphasizes the need for advanced biological screening, aligning with Lunai's strategic focus on AI-driven threat identification.

Immediate implications include strengthened partnerships and revenue streams enhancing Lunai's market position in biodefense.
Long-term implications involve the potential for significant growth in precision neurology and biodefense markets as government investment increases.

Potential risks include regulatory scrutiny and legal challenges related to the ongoing litigation against alleged market manipulation.
The company may face competition from other biotech firms and the complexities of navigating government contracts and partnerships.

Upcoming milestones include progress in litigation to restore shareholder value and advancements in biodefense and neurology programs.
The success of the Augusta platform and the expansion of partnerships in biodefense will signal Lunai's growth trajectory moving forward.

§ 07

What recent collaboration did Lunai Bioworks secure?

In April 2026, Lunai secured a revenue-generating, multi-year defense collaboration with BioSymetrics for AI-enabled chemical threat assessment.

Why is Lunai Bioworks' focus on biodefense important?

Lunai's initiatives position it at the forefront of biodefense and precision neurology, which are increasingly relevant to national security.

How does the 2027 Defense Authorization Bill relate to Lunai's strategy?

The bill emphasizes the need for advanced biological screening, aligning with Lunai's focus on AI-driven threat identification.